The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long-term outcomes and overall survival (OS) for zanidatamab + chemotherapy in HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinoma (mGEA): 4-year follow-up of a phase 2 trial.
 
Elena Elimova
Employment - Merck (I)
Honoraria - Daiichi Sankyo/Astra Zeneca; Roche Canada
Consulting or Advisory Role - Abbvie; Adaptimmune (Inst); Astellas Pharma; AstraZeneca; BeiGene; Bristol-Myers Squibb (Inst); Jazz Pharmaceuticals (Inst); Signatera; Viracta Therapeutics; Zymeworks (Inst)
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca Canada (Inst); Bold Therapeutics (Inst); Bristol-Myers Squibb (Inst); Jazz Pharmaceuticals (Inst); Jazz Pharmaceuticals (Inst); Zymeworks (Inst)
 
Jaffer Ajani
Honoraria - Acrotech Biopharma; Aduro Biotech; Amgen; Astellas Pharma; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Pharmaceuticals; Fresenius Kabi; Gilead Sciences; GRAIL; Lilly; Merck; Novartis; oncotherics; SERVIER; zymeworks
Consulting or Advisory Role - American Cancer Society; Amgen; Astellas Pharma; BeiGene; BeiGene; Bristol-Myers Squibb; Geneos; Gilead Sciences; Jazz Pharmaceuticals; Kyowa Kirin International; Merck; Novartis; SERVIER; Vaccinogen; Zymeworks
Research Funding - Amgen; Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb; Daiichi Sankyo; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; Merck; Novartis; ProLynx; Roche/Genentech; SERVIER (Inst); Taiho Pharmaceutical; Takeda; Zymeworks
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly
 
Howard Burris
Employment - Sarah Cannon Research Institute
Leadership - Sarah Cannon Research Institute; Torl Biotherapeutics
Stock and Other Ownership Interests - HCA Healthcare
Consulting or Advisory Role - AstraZeneca (Inst); Bicycle Therapeutics (Inst); GRAIL (Inst); Incyte (Inst); Roche (Inst); Vincerx Pharma (Inst)
Research Funding - Abbvie (Inst); Agios (Inst); Archer (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arvinas (Inst); AstraZeneca (Inst); BioAtla (Inst); Bristol-Myers Squibb (Inst); CALGB (Inst); Celgene (Inst); Coordination Pharmaceuticals (Inst); CytomX Therapeutics (Inst); EMD Serono (Inst); Foundation Medicine (Inst); Gossamer Bio (Inst); Harpoon therapeutics (Inst); Hengrui Therapeutics (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Kymab (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); Takeda/Millennium (Inst); Tesaro (Inst); TG Therapeutics (Inst); Verastem (Inst); Vertex (Inst); XBiotech (Inst); Zymeworks (Inst)
(OPTIONAL) Uncompensated Relationships - Bristol-Myers Squibb (Inst)
 
Crystal Denlinger
Employment - National Comprehensive Cancer Network
Leadership - National Comprehensive Cancer Network
Research Funding - 2seventy bio (Inst); Abbvie (Inst); Bluebird Bio (Inst); Bristol Myers Squibb (Inst); Genentech Foundation (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Sanofi (Inst)
 
Syma Iqbal
Honoraria - Astellas Scientific and Medical Affairs Inc; AstraZeneca; BeiGene; Exelixis; Jazz Pharmaceuticals; Merck
Consulting or Advisory Role - AstraZeneca; BeiGene; Cardiff Oncology; Exelixis; Jazz Pharmaceuticals; Merck
Speakers' Bureau - Astellas Pharma
Travel, Accommodations, Expenses - Astellas Pharma; BeiGene; Exelixis
 
Yoon-Koo Kang
Consulting or Advisory Role - DAEHWA Pharmaceutical; HLB
 
Jwa Hoon Kim
No Relationships to Disclose
 
Keun-Wook Lee
Honoraria - Astellas Pharma; Bayer; Daiichi Sankyo; Merck KGaA; Sanofi/Aventis
Consulting or Advisory Role - Abbvie; Astellas Pharma; Daiichi Sankyo; Metafines; MSD
Research Funding - ALX Oncology (Inst); Amgen (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Elevar Therapeutics (Inst); Erasca, Inc (Inst); Exelixis (Inst); Genome & Company (Inst); GlaxoSmithKline (Inst); Hanmi (Inst); IgM Biosciences (Inst); Ildong Pharmaceutical (Inst); InventisBio (Inst); Jazz Pharmaceuticals (Inst); Leap Therapeutics (Inst); Macrogenics (Inst); Medicenna (Inst); MedPacto (Inst); Merck KGaA (Inst); Metafines (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Panolos Bioscience (Inst); Roche (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); TRIO Oncology (Inst); Trishula Therapeutics (Inst); Wellmarker Bio (Inst); Y-BIOLOGICS (Inst)
(OPTIONAL) Uncompensated Relationships - ALX Oncology
 
Bruce Lin
Consulting or Advisory Role - Seagen
Research Funding - Compass Therapeutics; Exelixis; Genentech/Roche; GlaxoSmithKline; Incyte; Jazz Pharmaceuticals; Merck; Pfizer Cardiff Oncology; Relay Therapeutics; Taiho Oncology; Tvardi Therapeutics
 
Rutika Mehta
Honoraria - ASCO; Bristol-Myers Squibb
Consulting or Advisory Role - Arcus Biosciences; Astellas Pharma; BeiGene; Bristol-Myers Squibb; GlaxoSmithKline; Legend Biotech; Merck; natera; Novartis; Seagen
Research Funding - NCCN
 
Do-Youn Oh
Consulting or Advisory Role - Abbvie; Alligtor Bioscience AB; Arcus Biosciences; ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Eutilex; Genentech/Roche; Halozyme; Hana Pharm; Idience; IQVIA; J-Pharma; LG Chem; Merck Serono; Mirati Therapeutics; Moderna Therapeutics; MSD Oncology; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Yuhan; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER
 
Sun Young Rha
Consulting or Advisory Role - Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Daiichi Sankyo; Eisai; indivumed; LG Chem; MSD Oncology; Ono Pharmaceutical; Toray Industries
Speakers' Bureau - Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; BMS/Ono; Daiichi Sankyo/UCB Japan; Eisai; MSD Oncology
Research Funding - Amgen (Inst); ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daichii Sankyo; Eisai; Indivumed; Lilly; MSD Oncology; Roche/Genentech; Sillajen; Zymeworks
 
Chengzhi Xie
Employment - Jazz Pharmaceuticals
Stock and Other Ownership Interests - Jazz Pharmaceuticals
 
Diana Shpektor
Employment - Jazz Pharmaceuticals
Stock and Other Ownership Interests - Jazz Pharmaceuticals
 
Phillip Garfin
Employment - Jazz Pharmaceuticals; Zymeworks
Stock and Other Ownership Interests - Jazz Pharmaceuticals
 
Geoffrey Ku
Consulting or Advisory Role - Apexigen; AstraZeneca/Daiichi Sankyo; Bristol-Myers Squibb; I-Mab; Jazz Pharmaceuticals; Merck Sharp & Dohme; Pieris Pharmaceuticals
Research Funding - Adaptimmune (Inst); Arog (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); CARsgen Therapeutics (Inst); Daiichi Sankyo (Inst); Jazz Pharmaceuticals (Inst); Merck (Inst); Oncolys BioPharma (Inst); Pieris Pharmaceuticals (Inst); Triumvira Immunologics, Inc (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Aduro Biotech; AstraZeneca/MedImmune; Bristol-Myers Squibb; ImaBiotech; Merck Sharp & Dohme; Pieris Pharmaceuticals